Pfizer Inc.
PFE · New York Stock Exchange · Health Care
Shareholder advocacy aimed at Pfizer Inc.
9 recorded campaigns from 6 organizations.
Mercy Investment Services at Pfizer
Conduct a human rights impact assessment covering pricing and access to medicines.
Trinity Health at Pfizer
Set up and report on a process for weighing how stretching out patent protection affects patients' ability to get medicines, before applying for follow-on patents.
Interfaith Center on Corporate Responsibility members (lead filer not named in source) at Pfizer
Establish a process to evaluate how extended patent exclusivities affect product access when deciding whether to seek secondary and tertiary patents, and report the findings publicly.
Tara Health Foundation at Pfizer
Stop giving money to politicians and political committees working to restrict access to reproductive health care, or explain how that giving squares with what the company says it stands for.
Oxfam at Pfizer
Study the feasibility of transferring vaccine technology and know-how so that production can be scaled up and access improved around the world.
Oxfam America at Pfizer
Study the feasibility of transferring vaccine technology and know-how to ramp up production and improve sustainable access to its COVID-19 vaccine worldwide.
Trinity Health (Pfizer) and Oxfam America (Johnson & Johnson), with Interfaith Center on Corporate Responsibility members at Pfizer, Johnson & Johnson, Merck
Report on whether and how receipt of public funding for COVID-19 vaccines and treatments is taken into account in decisions affecting access, such as setting prices.
Members of the Interfaith Center on Corporate Responsibility at Pfizer Inc. and Merck & Co., Inc.
Disclose whether and how government financial support for research, development and manufacturing is considered in setting access and pricing strategies for COVID-19 vaccines and treatments.
Pressed Pfizer as a shareholder over the forced swim test, from the annual-meeting floor
A PETA scientist/shareholder challenged Pfizer executives from the floor of the April 25, 2019 annual meeting over the company's failure to adopt a no-forced-swim-test policy, alongside an outside protest. PETA later announced (undated precisely in sources reviewed) that Pfizer banned the test; the exact ban date and whether a formal 14a-8 resolution (as opposed to floor engagement) was filed at Pfizer specifically were not confirmed.
What shareholders voted on
From Pfizer Inc.’s own filings with the SEC. Support is the share of votes cast for and against, so abstentions and broker non-votes are not counted in it.
2026
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The proposal to approve, on an advisory basis, the 2026 compensation of the Company's Named Executive Officers | Say on pay | 88% | Passed | |
| The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year | Auditor | 92.8% | Passed | |
| Election of Cyrus Taraporevala | Director | 97.8% | Passed | |
| Election of James Quincey | Director | 97.4% | Passed | |
| Election of Ronald E. Blaylock | Director | 97.1% | Passed | |
| Election of Scott Gottlieb | Director | 96.3% | Passed | |
| Election of Susan Desmond-Hellmann | Director | 96% | Passed | |
| Election of Mortimer J. Buckley | Director | 96% | Passed | |
| Election of Dan R. Littman | Director | 95.4% | Passed | |
| Election of Shantanu Narayen | Director | 93.5% | Passed | |
| Election of James C. Smith | Director | 92.6% | Passed | |
| Election of Suzanne Nora Johnson | Director | 92.3% | Passed | |
| Election of Albert Bourla | Director | 92.3% | Passed | |
| Election of Joseph J. Echevarria | Director | 82.7% | Passed |
2025
2024
2023
2022
2021
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The shareholder proposal regarding independent chair policy | Shareholder proposal | 37.3% | Failed | |
| The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers | Say on pay | 92.8% | Passed | |
| The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2021 fiscal year | Auditor | 95.4% | Passed | |
| Election of Susan Hockfield | Director | 99.3% | Passed | |
| Election of Scott Gottlieb | Director | 99.3% | Passed | |
| Election of Susan Desmond-Hellmann | Director | 99.3% | Passed | |
| Election of Dan R. Littman | Director | 99.2% | Passed | |
| Election of James Quincey | Director | 98.9% | Passed | |
| Election of Shantanu Narayen | Director | 98.9% | Passed | |
| Election of Helen H. Hobbs | Director | 98.9% | Passed | |
| Election of James C. Smith | Director | 98.5% | Passed | |
| Election of Ronald E. Blaylock | Director | 97.9% | Passed | |
| Election of Suzanne Nora Johnson | Director | 95.8% | Passed | |
| Election of Albert Bourla | Director | 94.1% | Passed | |
| Election of Joseph J. Echevarria | Director | 84.8% | Passed |
2020
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers | Say on pay | 95% | Passed | |
| Susan Desmond-Hellmann | Company proposal | 99.3% | Passed | |
| The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2020 fiscal year | Auditor | 96% | Passed | |
| Election of Susan Hockfield | Director | 99.5% | Passed | |
| Election of Scott Gottlieb | Director | 99.5% | Passed | |
| Election of Helen H. Hobbs | Director | 99.4% | Passed | |
| Election of James Quincey | Director | 99.3% | Passed | |
| Election of Dan R. Littman | Director | 99.3% | Passed | |
| Election of Shantanu Narayen | Director | 99.2% | Passed | |
| Election of James C. Smith | Director | 98.9% | Passed | |
| Election of Ronald E. Blaylock | Director | 98.6% | Passed | |
| Election of W. Don Cornwell | Director | 97.7% | Passed | |
| Election of Suzanne Nora Johnson | Director | 95.8% | Passed | |
| Election of Albert Bourla | Director | 95.2% | Passed | |
| Election of Joseph J. Echevarria | Director | 92.3% | Passed | |
| Election of James M. Kilts | Director | 83.6% | Passed |
2019
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The shareholder proposal regarding integrating drug pricing into executive compensation policies and programs | Shareholder proposal | 28.7% | Failed | |
| The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers | Say on pay | 94.9% | Passed | |
| The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2019 fiscal year | Auditor | 96.4% | Passed | |
| Election of Albert Bourla | Director | 99.4% | Passed | |
| Election of Dan R. Littman | Director | 99.2% | Passed | |
| Election of Helen H. Hobbs | Director | 99.2% | Passed | |
| Election of Ian C. Read | Director | 98.9% | Passed | |
| Election of Shantanu Narayen | Director | 98.9% | Passed | |
| Election of James C. Smith | Director | 98.7% | Passed | |
| Election of Ronald E. Blaylock | Director | 98% | Passed | |
| Election of Suzanne Nora Johnson | Director | 97.1% | Passed | |
| Election of James M. Kilts | Director | 96.6% | Passed | |
| Election of Joseph J. Echevarria | Director | 95.8% | Passed | |
| Election of W. Don Cornwell | Director | 95% | Passed |
2018
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The shareholder proposal regarding report on lobbying activities | Shareholder proposal | 33.5% | Failed | |
| The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers | Say on pay | 92.6% | Passed | |
| The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2018 fiscal year | Auditor | 96.7% | Passed | |
| Election of Helen H. Hobbs | Director | 99.3% | Passed | |
| Election of Dan R. Littman | Director | 99.2% | Passed | |
| Election of James C. Smith | Director | 98.7% | Passed | |
| Election of Shantanu Narayen | Director | 98.4% | Passed | |
| Election of Dennis A. Ausiello | Director | 98.1% | Passed | |
| Election of Ronald E. Blaylock | Director | 98% | Passed | |
| Election of Albert Bourla | Director | 97.1% | Passed | |
| Election of Suzanne Nora Johnson | Director | 97% | Passed | |
| Election of Joseph J. Echevarria | Director | 96.9% | Passed | |
| Election of James M. Kilts | Director | 96.1% | Passed | |
| Election of Ian C. Read | Director | 95.2% | Passed | |
| Election of W. Don Cornwell | Director | 95.2% | Passed |
Proxy statements and vote results
Straight from Pfizer Inc.’s own SEC filings. The proxy statement lists what shareholders were asked to vote on; the 8-K certifies how the vote went.
| Year | Filing | Filed |
|---|---|---|
| 2026 | Vote results | 2026-04-27 |
| 2026 | Proxy statement | 2026-03-12 |
| 2025 | Vote results | 2025-04-28 |
| 2025 | Proxy statement | 2025-03-13 |
| 2024 | Vote results | 2024-04-29 |
| 2024 | Proxy statement | 2024-03-14 |
| 2023 | Vote results | 2023-05-01 |
| 2023 | Proxy statement | 2023-03-16 |
| 2022 | Vote results | 2022-05-02 |
| 2022 | Proxy statement | 2022-03-17 |
| 2021 | Vote results | 2021-04-26 |
| 2021 | Proxy statement | 2021-03-12 |
| 2020 | Vote results | 2020-04-24 |
| 2020 | Proxy statement | 2020-03-13 |
| 2019 | Vote results | 2019-04-29 |
| 2019 | Proxy statement | 2019-03-14 |
| 2018 | Vote results | 2018-05-01 |
| 2018 | Proxy statement | 2018-03-15 |
Do you represent Pfizer Inc.? Claim this profile to respond to the campaigns listed here.